ClinicalTrials.Veeva

Menu

STRucturation of Transcript Analysis of Genes Involved in Hereditary Cancers (STRATEGIC)

U

University Hospital, Rouen

Status

Enrolling

Conditions

Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT06861621
IDRCB : 2023-A00488-37 (Other Identifier)
2022/310/OB

Details and patient eligibility

About

Molecular diagnosis using high throughput sequencing has become an essential part of oncogenetic care, making it possible to identify people at risk, to guide surveillance, and to direct preventive surgery and treatment. The quality of this 'precision' care depends on the quality of the interpretation of the genomic variants identified. To be usable in oncogenetics, a genomic variant must be correctly interpreted: pathogenic, benign or of uncertain significance (VSI). The impact of these DNA variants (VSI) on RNA is particularly important for interpretation. Today, due to a lack of resources, joint and systematic DNA/RNA analysis is never carried out. This has inevitably meant that a number of situations of interest have been overlooked. It is now important to go a step further and organise a visible and reliable circuit, allowing routine access to these studies for patients.

Full description

Systematic DNA/RNA analysis is never carried out using the current approach, due to a lack of resources. Strategies recommend pre-screening variants using in silico analysis, followed by RNA studies targeting variants of interest.

Enrollment

1,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Over 18 years of age
  • Patients seen in oncogenetic consultations and who have given their informed consent for genetic analysis in the context of a major predisposition to breast, ovarian or digestive cancer.
  • Person who has read and understood the information note and does not object to taking part in the study
  • Membership of a social security scheme

Exclusion criteria

  • Minors
  • Persons deprived of their liberty or adults under guardianship or incapable of giving their consent
  • Failure to obtain informed consent

Trial contacts and locations

2

Loading...

Central trial contact

David MALLET, Director; Vincent FERRANTI, Arc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems